This study is completed in the United States, in the United Kingdom, in Belgium, .... It is testing guanfacine hydrochloride for ADHD.
ADHDDrugFrom 6 Years to 17 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether TAK-503 may be useful for adolescents experiencing ADHD.
What would participation involve?
Participants may receive TAK-503, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Austria, in Belgium, and in Germany.
Who is it mainly for?
This study appears to be mainly for adolescents with ADHD. Because it involves minors, a parent or guardian may need to be involved.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, what role parents or guardians have in the process.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateStarted: September 18, 2019
Recruitment status
Completed
Enrollment listed in the registry
396
Sponsor
Shire
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug, OTHER
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States, United Kingdom, Belgium, ...
Age range
From 6 Years to 17 Years
Official registry ID
NCT04085172
Official title
A Phase 4, Multicenter, 2-part Study Composed of a Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity Disorder
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Austria · 2 sites
LKH-Klinikum Graz
Graz
Site status: Not listed — confirm with the team
Medizinische Universtität Wien
Vienna
Site status: Not listed — confirm with the team
Belgium · 3 sites
UZ Brussel
Brussels
Site status: Not listed — confirm with the team
UPC KU Leuven Afdeling Kinderpsychiatrie ADHD-raadpleging
Leuven
Site status: Not listed — confirm with the team
Foyer Saint Francois
Namur
Site status: Not listed — confirm with the team
Germany · 4 sites
Zentralinstitut fuer Seelische Gesundheit
Mannheim, Baden-Wurttemberg
Site status: Not listed — confirm with the team
Universitaetsklinikum Koeln
Cologne, North Rhine-Westphalia
Site status: Not listed — confirm with the team
Rheinhessen-Fachklinik Mainz
Mainz, Rhineland-Palatinate
Site status: Not listed — confirm with the team
Universitaetsklinikum Freiburg
Freiburg im Breisgau
Site status: Not listed — confirm with the team
Netherlands · 2 sites
EB FlevoResearch
Almere Stad
Site status: Not listed — confirm with the team
EB UtrechtResearch
Utrecht
Site status: Not listed — confirm with the team
Portugal · 6 sites
Hospital de Cascais - Dr. José de Almeida
Alcabideche
Site status: Not listed — confirm with the team
Centro Clinico Academico 2CA Associacao Braga, Hospital de Braga Piso 1, Ala E
Braga
Site status: Not listed — confirm with the team
Centro Hospitalar Universitario Cova da Beira, E.P.E
Covilha
Site status: Not listed — confirm with the team
Hospital da Senhora da Oliveira Guimarães
Guimarães
Site status: Not listed — confirm with the team
Hospital CUF Descobertas
Lisbon
Site status: Not listed — confirm with the team
Centro Materno Infantil do Norte (CMIN) Centro Hospitalar Universitario do Porto
Porto
Site status: Not listed — confirm with the team
Spain · 8 sites
Clinica Universidad de Navarra
Pamplona, Navarre
Site status: Not listed — confirm with the team
Hospital Universitari Vall d'Hebron
Barcelona
Site status: Not listed — confirm with the team
Clinica Dr. Quintero
Madrid
Site status: Not listed — confirm with the team
Hospital Infanta Leonor
Madrid
Site status: Not listed — confirm with the team
Hospital Universitario Fundacion Alcorcon
Madrid
Site status: Not listed — confirm with the team
Complejo Hospitalario de Palencia
Palencia
Site status: Not listed — confirm with the team
Corporacio Sanitaria Parc Tauli
Sabadell
Site status: Not listed — confirm with the team
Instituto Valenciano de Neurología Pediátrica (INVANEP)
Valencia
Site status: Not listed — confirm with the team
Sweden · 3 sites
Barnneuropsykiatriska enheten, Sahlgrenska University hospital
Gothenburg
Site status: Not listed — confirm with the team
Regionhälsan
Mölnlycke
Site status: Not listed — confirm with the team
PRIMA Barn- och Vuxenpsykiatri AB
Norsborg
Site status: Not listed — confirm with the team
United Kingdom · 2 sites
Tayside Children Hospital
Dundee
Site status: Not listed — confirm with the team
Lister Hospital
Stevenage
Site status: Not listed — confirm with the team
United States · 20 sites
Harmonex Neuroscience Research
Dothan, Alabama
Site status: Not listed — confirm with the team
Advanced Research Center, Inc.
Anaheim, California
Site status: Not listed — confirm with the team
Sun Valley Research Center, Inc.
Imperial, California
Site status: Not listed — confirm with the team
Alliance Research
Long Beach, California
Site status: Not listed — confirm with the team
PCSD Feighner Research
San Diego, California
Site status: Not listed — confirm with the team
Homestead Medical Research
Homestead, Florida
Site status: Not listed — confirm with the team
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida
Site status: Not listed — confirm with the team
Care Research Center, Inc.
Miami, Florida
Site status: Not listed — confirm with the team
Clinical Neuroscience Solutions, Inc.
Orlando, Florida
Site status: Not listed — confirm with the team
AMR Conventions Research, Ltd
Naperville, Illinois
Site status: Not listed — confirm with the team
Collective Medical Research LLC
Prairie Village, Kansas
Site status: Not listed — confirm with the team
Qualmedica Research, LLC
Bowling Green, Kentucky
Site status: Not listed — confirm with the team
Qualmedica Research, LLC
Owensboro, Kentucky
Site status: Not listed — confirm with the team
Alivation Research, LLC
Lincoln, Nebraska
Site status: Not listed — confirm with the team
Center for Psychiatry and Behavioral Medicine, Inc.
Las Vegas, Nevada
Site status: Not listed — confirm with the team
University of Cincinnati
Cincinnati, Ohio
Site status: Not listed — confirm with the team
Cutting Edge Research Group
Oklahoma City, Oklahoma
Site status: Not listed — confirm with the team
Clinical Neuroscience Solutions, Inc.
Memphis, Tennessee
Site status: Not listed — confirm with the team
Family Psychiatry of The Woodlands
The Woodlands, Texas
Site status: Not listed — confirm with the team
Clinical Research Partners, LLC
Petersburg, Virginia
Site status: Not listed — confirm with the team
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT04085172. We help you review the study, but cannot decide medical eligibility.
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with adhd. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, Placebo. Phase 4 studies usually happen after treatment approval, to monitor real-world use.
Who might this study be for?
This study may concern people with adhd; age range: From 6 Years to 17 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Shire, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
